Nuchido TIME+ is UK-developed multi-precursor NAD+ formula targeting both NAD+ synthesis and CD38 degradation; backed by published in-vitro data showing higher NAD+ uplift than NR alone. Launched in 2020 by Nuchido, it delivers a multi-pathway NAD+ blend at approximately $80 per month at standard dosing. This review covers what's in the bottle, how it compares to peer brands, and whether it's worth the price for your goals.

NAD+ (nicotinamide adenine dinucleotide) is a redox coenzyme present in every cell. It powers mitochondrial ATP production via the electron-transport chain, fuels DNA-repair enzymes (PARPs), and is the obligatory substrate for sirtuins (SIRT1–SIRT7) — the enzyme family that controls gene expression, inflammation, and cellular survival.

NAD+ levels fall by 50% or more between ages 30 and 60. That decline is now considered a leading mechanistic explanation for age-related metabolic dysfunction, mitochondrial fatigue, accumulation of senescent cells, and the loss of muscle, skin, and cognitive resilience seen in aging.

NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are the two NAD+ precursors with the strongest human data. Both raise NAD+ via the salvage pathway: NR is phosphorylated by NRK1/NRK2 to form NMN, then converted to NAD+; NMN is dephosphorylated to NR for cellular uptake or — per Imai's lab — taken up directly through the Slc12a8 transporter in mouse small intestine. NADH is the reduced electron-carrying form. Niacinamide (nicotinamide) and niacin (nicotinic acid) are cheaper but raise NAD+ less efficiently, and high-dose nicotinamide (>1 g/day) inhibits sirtuins.

CD38, an NAD+-degrading enzyme, rises with age. Inhibitors of CD38 — apigenin, quercetin, luteolin — preserve the NAD+ you make. Methylation cofactors (TMG, B12, folate) become depleted with high-dose precursor use because the body methylates excess nicotinamide for excretion.